NOVAREX Co.,Ltd. (KOSDAQ:194700)
14,340
-400 (-2.71%)
At close: Feb 6, 2026
NOVAREX Revenue
NOVAREX had revenue of 113.84B KRW in the quarter ending September 30, 2025, with 47.33% growth. This brings the company's revenue in the last twelve months to 385.76B, up 32.12% year-over-year. In the year 2024, NOVAREX had annual revenue of 297.73B, down -1.47%.
Revenue (ttm)
385.76B
Revenue Growth
+32.12%
P/S Ratio
0.66
Revenue / Employee
831.37M
Employees
464
Market Cap
253.85B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 297.73B | -4.44B | -1.47% |
| Dec 31, 2023 | 302.17B | 20.49B | 7.28% |
| Dec 31, 2022 | 281.68B | 2.89B | 1.04% |
| Dec 31, 2021 | 278.79B | 55.96B | 25.11% |
| Dec 31, 2020 | 222.83B | 63.73B | 40.06% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| DongKoo Bio & Pharma | 238.39B |
| Kyung Dong Pharmaceutical | 193.64B |
| GREEN CROSS WellBeing | 151.06B |
| DAE HWA Pharmaceutical | 149.47B |
| OPTUS Pharmaceutical | 87.58B |
| High Tech Pharm | 75.60B |
| Vivozon Pharmaceutical | 66.40B |
| BL Pharmtech | 6.98B |